Provention Bio (NASDAQ:PRVB) stock observed trading -47.33% off 52-week high price. On the other end, the stock has been noted 313.06% away from low price over the last 52-weeks. The stock disclosed a move of 23.64% away from 50 day moving average and 14.66% away from 200 day moving average. Moving closer, we can see that shares have been trading 10.67% off 20-day moving average. It has market cap of $611.94M.

On May 07, 2020, Provention Bio (NASDAQ:PRVB) a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, revealed financial results and provided a business update for the first quarter ended March 31, 2020.

Public health and clinical research conditions have changed dramatically in recent months. As an agile, virtual company, Provention has adapted quickly and seamlessly to this challenging new operating environment, said Ashleigh Palmer, CEO of Provention Bio.

We continue to execute on our strategy to advance our lead candidate, teplizumab, as the first disease modifying therapy for patients who are at-risk of progressing to clinical-stage type 1 diabetes (T1D). To that end, last month we announced the first module of our rolling biologics license application (BLA) was submitted on schedule, and we remain on track to complete the submissions of all modules in Q4 2020. In parallel with these regulatory efforts, we are building a commercial team and laying the foundations to support a US launch if teplizumab is approved.

Additionally, we have reported progress on our development pipeline with positive Phase 1b study results for PRV-3279, highlighting this therapeutic candidate’s potential to intercept the pathophysiology of lupus and other B cell-mediated autoimmune diseases, as well as prevent or reduce the immunogenicity associated with certain biotherapeutics, including gene therapy products.

The USA based company Provention Bio moved with change of 2.12% to $12.02 with the total traded volume of 320612 shares in recent session versus to an average volume of 575.11K. The stock was observed in the 5 days activity at 5.07%. The one month performance of stock was 43.27%. PRVB’s shares are at -19.54% for the quarter and driving a 194.61% return over the course of the past year and is now at -19.33% since this point in 2018. The average volatility for the week and month was at 8.56% and 9.74% respectively. There are 50.91M shares outstanding and 32.56M shares are floated in market.